Savara Inc Payments to Acquire in Process Research and Development
Savara Inc (SVRA) reported Payments to Acquire in Process Research and Development of $3.25 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-30.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment · last filed 2022-03-30
- Savara Inc payments to acquire in process research and development for the quarter ending 2020-12-31 was $0.00.
- Savara Inc payments to acquire in process research and development for the quarter ending 2020-09-30 was $0.00.
- Savara Inc payments to acquire in process research and development for the quarter ending 2020-06-30 was $0.00.
- Savara Inc payments to acquire in process research and development for the quarter ending 2020-03-31 was $3.25M.
- Savara Inc payments to acquire in process research and development for fiscal 2020 was $3.25M.
| Period end | Payments to Acquire in Process Research and Development 3 month | Payments to Acquire in Process Research and Development 6 month | Payments to Acquire in Process Research and Development 9 month | Payments to Acquire in Process Research and Development 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $0.00 derived: sum of 2 quarters · filed 2022-03-30 | $0.00 derived: sum of 3 quarters · filed 2022-03-30 | $3.25M 10-K · filed 2022-03-30 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $3.25M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $3.25M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $3.25M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |